title: High incidence of graft failure in unrelated cord blood transplantation using a reduced-intensity preparative regimen consisting of fludarabine and melphalan.
authors.forename: H
authors.initials: H
authors.lastname: Narimatsu
authors.forename: M
authors.initials: M
authors.lastname: Watanabe
authors.forename: A
authors.initials: A
authors.lastname: Kohno
authors.forename: K
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Y
authors.initials: Y
authors.lastname: Kuwatsuka
authors.forename: T
authors.initials: T
authors.lastname: Uchida
authors.forename: M
authors.initials: M
authors.lastname: Murata
authors.forename: K
authors.initials: K
authors.lastname: Miyamura
authors.forename: Y
authors.initials: Y
authors.lastname: Morishita
mesh_terms: D036101:Cord Blood Stem Cell Transplantation / Q000009:adverse effects* / Q000379:methods; D005260:Female; D006085:Graft Survival; D006801:Humans; D008297:Male; D008558:Melphalan / Q000009:adverse effects*; D008875:Middle Aged; D019653:Myeloablative Agonists / Q000009:adverse effects*; D010865:Pilot Projects; D019172:Transplantation Conditioning / Q000009:adverse effects* / Q000379:methods; D017211:Treatment Failure; D014740:Vidarabine / Q000009:adverse effects / Q000031:analogs & derivatives*
chemical_list: D019653:Myeloablative Agonists; D014740:Vidarabine; C024352:fludarabine; D008558:Melphalan